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ABSTRACT
Members of the GHL ATPase superfamily, including
type II topoisomerases, Hsp90-class chaperones,
and MutL, all share a common GHKL-type ATP-
binding fold and act as nucleotide-controlled
‘molecular clamps’. These enzymes’ ATP-binding
sites have proven to be rich drug targets, and
certain inhibitors of type II topoisomerases and
Hsp90 bind to this region and competitively
inhibit these enzymes. Recently, it was found that
radicicol, a drug known to block Hsp90 function,
also inhibits the archaeal type IIB topoisomerase
topo VI. Here, we use X-ray crystallography to
show that despite low sequence identity ( 10–12%)
between topo VI and Hsp90, radicicol binds to the
ATPase sites of these two enzymes in an equivalent
manner. We further demonstrate that radicicol
inhibits both the dimerization of the topo VI ATPase
domains and ATP hydrolysis, two critical steps in the
enzyme’s strand passage reaction. This work con-
tributes to a growing set of structures detailing the
interactions between GHL-family proteins and vari-
ous drugs, and reveals radicicol as a versatile
scaffold for targeting distantly related GHL enzymes.
INTRODUCTION
Type II topoisomerases are essential enzymes that maintain
the structural and topological integrity of cellular DNA.
These enzymes are unique in their ability to pass one DNA
duplex through a transient double-stranded break in another,
a reaction controlled by the binding and hydrolysis of
two molecules of ATP (1–3). Through this activity, type II
topoisomerases can resolve a variety of potentially dangerous
DNA topologies, including supercoils, knots and catenanes
(4). Additionally, because cells need to appropriately
maintain DNA superstructure for growth and division,
many compounds that target type II topoisomerases exhibit
useful therapeutic properties (5–7).
The duplex passage reaction of type II topoisomerases
[reviewed in Ref. (3)] begins when the enzyme binds one
segment of DNA, known as the ‘gate’ or G-segment (8). A
second DNA, the ‘transfer’ or T-segment, is next trapped
inside the enzyme upon ATP-induced dimerization of the
nucleotide-binding domains (9,10). ATP binding and
T-segment capture in turn stimulate attack of the G-segment
by a pair of tyrosine residues, creating a reversible double-
stranded DNA break. A series of conformational changes,
likely facilitated by ATP hydrolysis, are subsequently propa-
gated through the enzyme to separate the two broken
G-segment ends, transport the T-segment though the break,
and expel the T-segment from the enzyme (8). Following
ATP hydrolysis and product release, the ATPase domains
dissociate, resetting the enzyme for another round of strand
passage (10,11).
Type II topoisomerases (topos) are divided into two
groups that share a common set of catalytic domains but
are structurally and evolutionarily distinct. The type IIA
enzymes, including bacterial DNA gyrase and topo IV,
eukaryotic topo II and phage type II topos, were discovered
over 30 years ago (12), and have been extensively studied
both biochemically and structurally [for reviews, see Refs.
(1–4)]. In contrast, relatively less is known about topo VI, a
type IIB enzyme ﬁrst isolated by Forterre and colleagues (13)
that has been found throughout archaea as well as in algae,
plants and a small number of bacteria (13–16). The ATPase
domains of topo VI are similar to those of its type IIA cousins
(14,17), but topo VI possesses a distinct DNA-binding and
cleavage subunit that is homologous to the meiotic recom-
bination factor Spo11 (14,18,19). Interestingly, despite the
differences between the DNA cleavage domains of the type
IIA and IIB topoisomerases, several drugs that affect G-
segment cleavage in eukaryotic enzymes (e.g. doxorubicin/
donorubicin and amsacrines) have been shown to also inhibit
topo VI (13). In contrast, drugs such as the coumarins, which
target the ATPase regions of bacterial type IIA topoi-
somerases, do not appear to cross-react with type IIB
enzymes (13).
The ATPase domains of all type II topoisomerases adopt a
GHKL fold, named for the founding members of this class:
DNA gyrase, Hsp90, bacterial histidine kinases and MutL
(14,20). Three of these enzyme families, including type II
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that possesses an additional domain and some common
mechanistic features (10,17,21). Despite their widely diverse
cellular functions, GHL enzymes are all ‘molecular clamps’:
type II topos and MutL trap substrates through ATP-
dependent dimerization of these domains (9,10,22), while
Hsp90 seems to use GHKL domain dimerization to facilitate
the release of bound substrates (23).
The evolutionary kinship between the ATPase domains of
different GHL enzymes recently prompted Forterre and
co-workers to test the ability of two Hsp90 inhibitors,
geldanamycin and radicicol, to inhibit type II topoisomerases
(24). While neither drug inhibited the bacterial type IIA
topoisomerase, DNA gyrase, radicicol was shown to effec-
tively inhibit strand passage by the archaeal type IIB enzyme
topo VI. This ﬁnding was remarkable, especially in light of
the very low sequence identity (10–12% identity) and
structural homology (6.5 s Ca r.m.s.d.) that exists between
the GHKL domains of topo VI and Hsp90. Based on
radicicol’s ability to inhibit topo VI and on molecular
modeling studies, Gadelle et al. (24) proposed that radicicol
likely acts on this enzyme as it does on Hsp90, by binding
to the ATPase site.
Here we show through crystallographic analyses that
radicicol inhibits topo VI by associating with the enzyme’s
ATP-binding pocket in a manner that closely mimics its
interaction with Hsp90. In addition, we show that radicicol
behaves similarly to competitive ATPase inhibitors of
bacterial type IIA topoisomerases, such as novobiocin (25),
and that it can effectively block nucleotide-mediated
dimerization of the topo VI ATPase subunit. These results
provide important mechanistic insights into the mode of
action of the ﬁrst drug identiﬁed to inhibit topo VI via its
ATPase subunit, and help further deﬁne the interplay between
drug structure and enzyme speciﬁcity for GHL-family
proteins.
MATERIALS AND METHODS
Cross-linking based dimerization assay
A near full-length fragment containing residues 2–470 of the
Sulfolobus shibatae topoisomerase VI B-subunit (topoVI-B0)
was prepared as described previously (17). Puriﬁed topoVI-B0
was diluted to 2 mg/ml in a buffer containing 20 mM HEPES
(pH 7.5), 400 mM NaCl, 10% glycerol and 1% dimethyl
sulfoxide (DMSO) (from radicicol stock solution), along
with 1 mM of either ADP, AMP-PNP or radicicol (Sigma).
When both nucleotide and radicicol were included, the
protein was pre-incubated with 1 mM radicicol at room tem-
perature for 30 min before nucleotide addition. Reactions were
incubated at 65 C for 10 min and slow-cooled (1 C/min)
to room temperature in a hot-top thermocycler to minimize
evaporation (dimerization was not observed without a high-
temperature incubation, presumably because of the ther-
mophilic nature of the enzyme). Samples were then diluted
8-fold in buffer and fresh glutaraldehyde was added to
0.025%. After 20 min, 10 ml aliquots were removed and
quenched with 5 ml 2 M glycine. Finally, 10 ml SDS–PAGE
loading dye was added and 15 ml of each sample was run on
an 8% SDS–polyacrylamide gel.
ATPase assay
ATPase assays were performed using a modiﬁed malachite
green/molybdate assay for free phosphate as described
previously, with adjustments to reduce sample volume and
increase assay sensitivity (26,27). Reactions (25 ml) contained
10 mM topoVI-B0, 1 mM ATP and varying amounts of
radicicol (20 mM to 1 mM) in a buffer composed of
20 mM HEPES (pH 7.5), 300 mM NaCl, 5% glycerol,
1 mM DTT and 1% DMSO (from radicicol stock
solution). Reactions were initiated with the addition of
enzyme and incubated for 20 min at 75 C in a hot-top
thermocycler. After incubation, 64.5 ml of assay reagent
[two parts 0.0675% (w/v) malachite green in water, one
part 5% (w/v) ammonium molybdate tetrahydrate in 4 M
sulfuric acid, mixed and ﬁltered the day of the assay] was
added to each reaction. After 1 min, 10.5 ml of 34% (w/v)
sodium citrate in water was added to quench the reaction
and minimize acid hydrolysis of remaining ATP. Color was
allowed to develop for 30 min, and a Perkin-Elmer Victor3V
plate reader recorded absorbance with an excitation ﬁlter
at 665 nm (7.5 nm bandpass). All reactions were performed
in triplicate.
Crystallization, data collection and structure solution
For co-crystallization trials, topoVI-B0 (10–15 mg/ml)
was dialyzed overnight against 20 mM HEPES (pH 7.5),
100 mM NaCl and 5 mM MgCl2. After dialysis, radicicol
was added to 1 mM (from a 100 mM stock in DMSO), and
the mixture was incubated at room temperature for 30 min
before setting crystal trays.
Crystallization was performed in microbatch format under
parafﬁn oil. Dialyzed topoVI-B0 was mixed 1:1 with well
solution containing 250 mM magnesium acetate, 24% PEG-
3350 and 100 mM HEPES (pH 7.5) at 19 C. Following
crystallization, the drop was ﬂooded with cryoprotectant
containing an additional 25% glycerol, and crystals (ﬂat
plates  0.4 · 0.4 · 0.02 mm) were looped and ﬂash-frozen
in liquid nitrogen.
All datasets were collected on Beamline 8.3.1 at the
Advanced Light Source at Lawrence Berkeley National
Laboratory (28). Diffraction data were indexed and
reduced with ELVES (29) using MOSFLM (30). Molecular
replacement was performed with PHASER (31), using the
previously reported monomeric apo structure of topoVI-B0
(PDB ID 1MU5) (17) as a search model. To avoid
biasing the reﬁnement process, we used a free-R set
identical to that used in the original reﬁnement of the search
model. Reﬁnement and placement of ordered water molecules
was carried out using a Refmac/ARP procedure (32,33),
followed by TLS reﬁnement as implemented in Refmac5
(34). The ﬁnal model contains residues 10–470 of
topoVI-B0, with 98.7% of residues in favored regions and
no residues in disallowed regions of Ramachandran space.
Fo   Fc simulated-annealing omit maps were generated
by CNS (35,36). Buried surface area was computed
with AREAIMOL (37), and surface complementarity by SC
(37,38). Figures were produced with PyMOL (39). Coordi-
nates have been deposited in the RCSB PDB under accession
no. 2HKJ.
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Radicicol inhibits ATP hydrolysis and
nucleotide-mediated dimerization of topo VI-B0
We have described previously the puriﬁcation and crystalliza-
tion of the isolated 470 amino acid ATPase region of the
S.shibatae topo VI B-subunit (topoVI-B0) (17). This construct
consists of the GHKL ATP-binding domain, as well as a
C-terminal ‘transducer’ domain that is involved in nucleotide
turnover and likely acts to sense and respond to ATP- and/or
T-segment binding (10,11). These domains are separated by a
small helix-two turns-helix (H2TH) domain of unknown
function, which is not shared with other type II topos or
Hsp90. The C-terminal 60 amino acids of topoVI-B, respon-
sible for interaction with the A-subunit (17), are truncated in
the topoVI-B0 construct.
To test whether radicicol acts on topo VI through the
enzyme’s ATPase domains, we ﬁrst measured the drug’s
effect on ATP hydrolysis by the topoVI-B0 construct.
Figure 1A shows that radicicol signiﬁcantly impairs the
ATPase activity of topoVI-B0 at concentrations equivalent
to those in which it has been shown to inhibit strand passage
(24). These data indicate that the nucleotide-binding site of
topo VI comprises the site of radicicol action.
Since dimerization of the ATPase domains is also depen-
dent on ATP-binding, we next sought directly to determine
the effect of radicicol on the dimerization of topoVI-B0.I f
the drug were to interact directly with the ATP-binding site
of topo VI, it could impair strand passage either by inhibiting
dimerization of the GHKL domains, or by ‘locking’ them in a
dimeric state that is impaired in its ability to release hydrol-
ysis products. Precedent for both of these mechanisms can be
found in different drugs that target type IIA topoisomerases.
For example, bisdioxopiperazines bind between the dimer-
ized GHKL domains of eukaryotic topo II and hold this inter-
face closed (40,41). In contrast, novobiocin inhibits bacterial
type IIA topoisomerases by impeding ATP binding and
GHKL domain dimerization (25,42). Since radicicol was
expected to bind directly to the ATP-binding pocket of
topoVI-B0 (24), we anticipated that its activity would more
closely mimic that of novobiocin.
To test this assumption, we made use of a dimerization
assay for topoVI-B0 based on glutaraldehyde cross-linking
(11). We have shown previously that topoVI-B0 is monomeric
in solution in the absence of nucleotide, and that ATP or
a non-hydrolyzable analog is able to induce measurable
amounts of dimerization (11). As shown in Figure 1B, radici-
col on its own does not promote dimerization of topoVI-B0.
The drug also effectively inhibits nucleotide-dependent
dimerization when pre-incubated with the protein. Together
with the results of our ATPase assays, these data support
the idea that radicicol inhibits topo VI by binding to the
ATPase site of the enzyme’s B-subunit, preventing both
ATP binding and GHKL domain homo-dimerization.
The structure of topoVI-B0 bound to radicicol
Since radicicol effectively inhibits topo VI strand passage
activity (24), ATP turnover, and nucleotide-dependent
GHKL domain dimerization, we next set out to directly
visualize the drug’s binding to topoVI-B0. We attempted to
crystallize a topoVI-B0–radicicol complex in conditions
matching those previously reported for either dimeric or
monomeric forms of the protein (17). In accord with the
results of our dimerization assay, we were only able to
grow crystals of the complex in the monomeric state. Using
diffraction data collected from these crystals, we solved the
structure by molecular replacement to a resolution of 2.0 s
(Table 1).
The structure of the topoVI-B0–radicicol complex is shown
in Figure 2. The drug binds to the topoVI-B0 GHKL domain
Figure 1. The effect of radicicol on ATP turnover and nucleotide-induced
dimerization of topoVI-B0.( A) Radicicol inhibits ATP hydrolysis by
topoVI-B0. Since the intrinsic ATPase activity of the isolated topoVI-B0
subunit is very low ( 0.11 ATP hydrolyzed per minute per subunit), the
observed residual activity may be attributable to a contaminating ATPase
activity i.e. radicicol-resistant. Error bars indicate the standard deviation
between three trials conducted in parallel. (B) Radicicol blocks dimerization
of topoVI-B0. Glutaraldehyde based cross-linking dimerization assay,
performed in the presence and absence of radicicol and the non-hydrolyzable
ATP analog, AMP-PNP. Radicicol does not stimulate dimerization on its
own (lane 2), and significantly inhibits dimerization mediated by AMP-PNP
when pre-incubated with the protein (lane 4). For this assay, the drug was
pre-incubated with topoVI-B0 to avoid detecting any dimers that may form
before equilibrium is reached, since AMP-PNP-mediated dimerization is
essentially irreversible.
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aromatic ring binding in the interior of the ATP-binding
pocket and the macrocycle draping over the outer edge of
the pocket. Radicicol interacts with topoVI-B0 through
several water-mediated hydrogen bonds, two direct hydrogen
bonds between exocyclic oxygen atoms of the aromatic ring
and the side chains of Asp76 and Thr170, and van der Waals
interactions between the exocyclic chlorine atom and the side
chains of Val112 and Phe90. In addition to these speciﬁc
contacts, there are several van der Waals contacts between
the macrocycle ring and surrounding hydrophobic residues,
resulting in excellent overall shape complementarity between
the drug and its binding site (Figure 2 and Table 2).
Comparison of radicicol- and AMP-PNP-bound forms of
topoVI-B0 shows that the drug binding site directly overlaps
with that of the nucleotide (Figure 3A and B). Further inspec-
tion also reveals why the drug is unable to mediate dimeriza-
tion of the subunit. When AMP-PNP (a non-hydrolyzable
ATP analog) binds to the GHKL domain of topoVI-B0, the
ATP lid (residues 107–111) drapes across the g-phosphate
moiety, and an adjacent loop (residues 97–106) rearranges
to interact directly with the ribose and b-phosphate groups
of the nucleotide. These structural changes in turn allow
 10 residues from the extreme N-terminus of the dimer
mate (a region termed the ‘strap’) to drape across this loop
and effectively lock the dimer together (10,11). In contrast,
radicicol binding does not induce the rearrangement of either
the ATP lid or the adjacent loop. Indeed, the drug may
actively inhibit these changes, as it lacks similarity to adenine
in both shape and chemical nature (Figure 3B), and appears
unable to support hydrogen bonding interactions needed for
the conformational rearrangements that accompany binding
of the N-terminal strap.
Comparison of radicicol binding to other drugs
targeting type II topoisomerase ATPase domains
Type II topoisomerases from bacteria, archaea and eukaryotes
all share a common set of ATPase domains (10,17,40). Thus,
it is noteworthy that, of the several classes of drugs that
inhibit type II topoisomerases by targeting their ATPase
domains, most act on only a subset of family members. For-
tunately, complexes between several of these drugs and their
respective targets have been amenable to analysis by X-ray
crystallography, allowing a detailed comparison of their
modes of action and unique speciﬁcity determinants (43).
One class of drugs, the bisdioxopiperazines, associates
with the GHKL domains of eukaryotic type II topoisomerases
and inhibits the enzyme non-competitively (44). Bisdiox-
opiperazines have been shown to act by binding in a cavity
between dimer-related GHKL domains, effectively locking
these two subunits together to prevent the enzyme from turn-
ing over (40). The bisdioxopiperazines speciﬁcally target
eukaryotic type IIA topoisomerases because the cavity in
which they bind is not conserved in the bacterial type IIA
or archaeal type IIB topos (40). This mode of action is dis-
tinctly different from that of radicicol, which blocks dimer-
ization of the GHKL domains of topo VI (Figure 1B).
A more informative study can be undertaken by comparing
the action of radicicol with that of compounds targeting bac-
terial type IIA topoisomerases, in particular DNA gyrase.
Complexes between the Escherichia coli GyrB subunit and
coumarin drugs (novobiocin and chlorobiocin), as well as a
peptide-based cyclothialidine analog (GR122222X), have
been studied crystallographically, and show that both of
these drug classes inhibit strand passage by competitively
binding to the ATPase site (25,45,46). In this respect, the
action of these drugs parallels that of radicicol. Moreover,
overlays of co-crystal structures indicate that these drugs’
binding sites overlap with the adenine of bound nucleotide,
as is seen for radicicol, and that the compounds likewise pos-
sess no structural analog to the ribose sugar or phosphate
moieties (Figure 3C and D).
Despite these similarities, a comparison of the radicicol-
binding site in topoVI-B0 with that seen for novobiocin and
GR122222X in E.coli GyrB reveals the structural basis for
these compounds’ distinct speciﬁcities. All three drugs inter-
act with two highly conserved residues, Asp76
topoVI-B0
/
Asp73
GyrB and Thr170
topoVI-B0
/Thr165
GyrB, which directly
contact ATP in all type II topoisomerases. Radicicol and
GR122222X are also liganded by the main chain nitrogen
of Gly80
topoVI-B0
/Gly77
GyrB and the main chain carbonyl oxy-
gen of Leu39
topoVI-B0
/Val43
GyrB, residues that ligand either
ATP or Mg
2+ in both topoVI-B0 and GyrB. However, novo-
biocin and GR122222X further interact with another con-
served residue, Asn42
topoVI-B0
/Asn46
GyrB, which radicicol
does not contact. Moreover, whereas radicicol nestles almost
entirely inside the ATP-binding pocket, large segments of
novobiocin and GR122222X lie outside the pocket and con-
tact residues that are not conserved across type II topoiso-
merases. For example, both novobiocin and GR122222X
ligand Arg136 of GyrB, an amino acid that lies outside the
Table 1. Data collection, refinement and stereochemistry
Data collection
Resolution (A ˚) 50–2.0
Wavelength (A ˚) 1.1157
Space group P21212
Unit cell dimensions (a, b, c) A ˚ 93.88, 111.40, 54.89
Unit cell angles (a, b, g)  90.0, 90.0, 90.0
I/s (last shell) 10.5 (2.2)
Rsym (last shell) %
a 6.4 (32.2)
Completeness (last shell) % 99.0 (94.6)
No. of reflections 143571
Unique 39306
Refinement
Resolution (A ˚) 30.0–2.0
No. of reflections 35959
Working 32723
Free (% total) 3236 (8.3%)
Rwork (last shell) (%)
b 16.67 (22.4)
Rfree (last shell) (%)
b 20.88 (27.2)
Structure and Stereochemistry
No. of atoms 4089
Protein 3704
Water 355
Radicicol 25
Magnesium 1
DMSO 4
R.m.s.d. bond lengths (A ˚) 0.015
R.m.s.d. bond angles ( ) 1.410
aRsym ¼ SSj|Ij  h Iij/SIj, where Ij is the intensity measurement for reflection
j and hIi is the mean intensity for multiply recorded reflections.
bRwork, free ¼ Sk Fobs|   |Fcalck/|Fobs|, where the working and free R-factors are
calculated using the working and free reflection sets, respectively. The free
reflections were held aside throughout refinement.
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archaeal or eukaryotic enzymes. Additionally, inside the
ATP-binding pocket, GR122222X interacts with Glu50 of
GyrB, which is substituted with alanine in topoVI-B0. This
residue may be partly responsible for the natural resistance
of gyrase to radicicol (24), since the larger glutamate residue
in GyrB appears positioned to occupy the space needed to
accommodate radicicol. Thus, despite the similarities
between these three drugs’ binding sites, structural and
chemical differences between type II topoisomerase subfami-
lies, largely in residues other than those that bind ATP, help
explain particular binding speciﬁcities.
Comparison of radicicol binding to topoVI-B0
and Hsp90
The GHKL domains of topo VI and Hsp90 share only
  10–12% sequence identity. Unsurprisingly, the structures
of their GHKL domains are likewise fairly divergent: 107 Ca
atoms in core secondary structural elements can be closely
aligned with an r.m.s.d. of 1.9 s, but over the length of their
GHKL domains, the Ca r.m.s.d. exceeds 6 s [Saccharomyces
cerevisiae Hsp90, PDB ID 1BGQ, Ref. (47)] (Figure 4A).
Despite these differences, the majority of amino acids and
ordered water molecules that interact with radicicol in Hsp90
are shared with topoVI-B0, and overlay almost exactly when
the two structures are compared (Figure 4B and Table 2). The
commonligandinginteractionsincludeseveralwater-mediated
hydrogen bonds, a direct hydrogen bond to Asp76
topoVI-B0
/
Asp79
Hsp90, and a van der Waals contact with Phe90
topoVI-B0
/
Phe124
Hsp90. In the latter instance, it is interesting to note
Figure 2. The structure of monomeric topoVI-B0 bound to radicicol. (A) Ribbon diagram of the topoVI-B0-radicicol complex. The GHKL domain is shown in
yellow, the H2TH domain purple, and the transducer domain orange. Radicicol is shown as spheres, bound to the GHKL domain. (B) Stereo view of the
interactions between radicicol and topoVI-B0.( C) Simulated-annealing omit Fo   Fc difference density for radicicol bound to topoVI-B0. Density in gray is
shown contoured at 2.5 s, and in blue at 10 s around the exocyclic chlorine atom. (D) A view of radicicol (sticks) and its coordinating water molecules (spheres)
in its binding pocket in topoVI-B0 (yellow surface), highlighting the shape complementarily between the drug and protein.
Table 2. Comparison of radicicol interactions in topoVI-B0 and Hsp90
Radicicol atom TopoVI-B0
interacting
residue
Hsp90
interacting
residue
Oxygen 1
a ——
Oxygen 2 Thr170 —
Asp76
b Asp79
Oxygen 3 (Gly80)
c (Gly83)
(Thr170) (Thr171)
Oxygen 4 (Leu39) (Leu34)
(Ser43)
Oxygen 5 (Ala89) —
Oxygen 6 (Asp45) Lys44
(His50)
Chlorine 1 Phe90
d,e Phe124
d
Asn42 Asn37
Val112
Carbon 2 Ile81 Met84
Carbon 17 Ile79 Ile82
TopoVI-B0-
radicicol
Hsp90-
radicicol
Buried protein
surface area (A ˚ 2)
f
233 258
Surface complementarity
(Sc)
f
0.763 0.728
aOxygen atoms are labeled by number in Figures 4C and D.
bUnderlines indicate interactions shared between topoVI-B and Hsp90.
cParentheses indicate water-mediated interactions.
dItalics indicate van der Waals interactions.
eThe phenylalanine residues from the two proteins originate from different
secondary structural elements.
fBuried surface area and surface complementarity were computed considering
three buried water molecules (best seen in Figure 2D) in each complex as part
of the ligand.
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space and form part of the hydrophobic ‘ceiling’ of the ATP-
binding pocket, yet they actually originate from different
secondary structural elements. Of the common radicicol-
interacting residues, only one, Asp76
topoVI-B0
/Asp79
Hsp90,i s
directly involved in nucleotide-binding; several others are
involved in water-mediated interactions with nucleotide. The
only major difference between the two proteins’ interactions
withradicicolliesoutside the ATP-binding site, at the epoxide
oxygen. Whereas topoVI-B0 interacts with this atom through
two water-mediated hydrogen bonds (Figure 2B), Hsp90 lig-
ands it directly through a lysine. Overall, the conservation
between the radicicol-binding sites of Hsp90 and topoVI is
remarkable, and explains why radicicol is able to bind these
evolutionarily diverged enzymes.
It should be noted that despite the similarities between the
two proteins’ binding sites, radicicol inhibits the ATPase
activity of S.cerevisiae Hsp90 at least 1000-fold more effec-
tively than is seen for S.shibatae topoVI-B0 (47) (Figure 1A).
The physical basis for this difference is not clear. The drug
buries approximately the same amount of surface area when
bound to either protein (Table 2). Respective surface comple-
mentarity (Sc) values for the two enzymes are highly similar
as well, and there are no obvious steric clashes between
topo VI and radicicol that might account for its reduced
inhibition. One possibility is that the epoxide oxygen of radi-
cicol, which associates directly with a lysine in Hsp90, but is
liganded indirectly through a water-mediated hydrogen bond
in topo VI, plays some role in tuning afﬁnity. Alternatively,
it is possible that the difference arises because of some
Figure 3. Comparison of radicicol, adenine nucleotide and coumarin drug binding to type II topoisomerases. (A) Structural overlay of the GHKL domains of
radicicol-bound (yellow/white) and AMP-PNP-bound (gray/magenta) topoVI-B0 (17). (B) Close-up stereo view of the overlay shown in (A), with the ATP lid and
adjacent loop residues 97–106 colored yellow (radicicol-bound) or magenta (AMP-PNP-bound, labeled). Radicicol competes for the same binding site as the
adenine moiety of a nucleotide, but does not mediate protein conformational changes that allow dimerization. (C) Structural overlay of the GHKL domains
of radicicol-bound topoVI-B0 (yellow/white) and the novobiocin-bound Thermus thermophilus GyrB dimer (gray/magenta) [Ref. (45), PDB code 1KIJ].
(D) Close-up stereo view of the overlay shown in (C). Both drugs bind in the ATPase site, but novobiocin additionally extends out of the active site to interact
with residues specific to GyrB proteins. The ATP lid and adjacent loop in GyrB are rearranged to allow dimerization. Novobiocin makes several contacts with
this region of GyrB (data not shown), but the interactions are not as extensive as those seen for bound nucleotide.
4274 Nucleic Acids Research, 2006, Vol. 34, No. 15necessary change in drug or protein structure that is slow to
occur on the time scale of the activity assays (but resolved
during the time required for crystallization), or that becomes
manifest at the markedly different working temperatures for
the two GHL proteins (30–37 C versus 65–80 C). Future
mutagenesis and biochemical studies will be needed to
explore this issue more thoroughly.
CONCLUSIONS
Our structural and biochemical results show that radicicol
inhibits topo VI function by acting as a competitive inhibitor
of ATP binding. Our ﬁndings also reveal that drug binding
blocks dimerization of the ATPase domains, an event critical
for T-segment capture and passage (Figure 5) (24). The abil-
ity of radicicol to speciﬁcally inhibit type IIB, but not type
IIA topoisomerases could allow for its use in vivo to dissect
the relative roles of type IIA and IIB topos in organisms that
contain both enzyme classes. These include several bacterial
species, certain archaea that contain a DNA gyrase evidently
gained through horizontal gene transfer (48), and plants,
where topo VI coexists with topo II and is required for a
specialized genome ampliﬁcation process known as endore-
duplication (16,49,50). Radicicol may also be useful for
exploring the molecular mechanisms of other GHL-family
Figure 4. Comparison of radicicol binding to topoVI-B0 and Hsp90. (A) Structural overlay of radicicol-bound topoVI-B0 (yellow) and Hsp90 (blue) [Ref. (47),
PDB code 1BGQ], superposed on the bound radicicol molecule. (B) Stereo view of an overlay between the active sites of topoVI-B0 (yellow with red waters) and
Hsp90 (blue with blue waters) bound to radicicol, showing a shared constellation of interacting amino acids and liganding water molecules (drug binding residues
not shared between the two enzymes are not shown in this panel). (C and D) Detailed views of the interactions of radicicol with topoVI-B0 (C) and Hsp90 (D).
Drug-liganding amino acids that are conserved between the two proteins are underlined, and oxygen and select carbon atoms of radicicol are numbered.
Nucleic Acids Research, 2006, Vol. 34, No. 15 4275enzymes. For example, modeling suggests that the drug could
ﬁt comfortably in the ATP-binding pocket of MutL, and may
bind topo II (data not shown).
Given the involvement of GHL enzymes in several critical
cellular processes, from protein folding to DNA topology
maintenance and repair, the design of new drugs to inhibit
these enzymes is a high priority (43). The availability of a
large set of structures showing GHL-family enzymes bound
to different drugs reveals fascinating patterns of speciﬁcity
combined with unexpected cross-reactivities. This situation
likely arises from the interplay between two factors: a high
degree of conservation within the ATP-binding site allows
certain drugs to cross-react with very divergent enzymes,
while structural differences outside this site concomitantly
permit more speciﬁc targeting. With its small size and evident
promiscuity in binding at least two highly diverged GHL-
family enzymes, radicicol may prove an attractive scaffold
on which to build more speciﬁc drugs that exploit unique
structural features of other GHL family members.
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